Full Press Release Details
Pharmaceuticals to Present at the 9th National Life Science &
Week ILSI -BIOMED Conference, Israel 2010
to present on Wednesday, June 16th at
Israel - June 8, 2010 - Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB); www.oramed.com), a
developer of oral delivery systems, today announced today that it was chosen to
present at the 9th National Life Science & Technology Week ILSI-BIOMED
Conference, Israel 2010. The presentation will be given by Nadav
Kidron, Chief Executive Officer of Oramed, on Wednesday, June 16th during
the BioPharma Session at 11:50 a.m. (IDT) at the David Intercontinental Hotel in
Event: National Life Science &
Technology Week ILSI-BIOMED Conference, Israel 2010
Date: Wednesday, June 16 2010
11:50 a.m. (IDT), or 4:50 a.m. (EST)
information about the upcoming ILSI Biomed conference, please visit the
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking to
revolutionize the treatment of diabetes through its patented flagship product,
an orally ingestible insulin capsule currently in Phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years of research
performed by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
information, please visit http://www.oramed.com.
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
and Investor Relation Contacts:
Pharmaceuticals Inc.